Print

Purpose

The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Migraine with or without aura fulfilling the International Headache Society (IHS) diagnostic criteria 1.1 and 1.2.1 - History of disabling migraine for at least 1 year - Migraine onset before the age of 50 years - History of 3 to 8 migraine attacks per month (<15 headache days per month) during the past 3 months - MIDAS score ≥11 - Able and willing to complete an eDiary to record the details of each migraine attack treated with study drug - Women of child-bearing potential must be using or willing to use a highly effective form of contraception - Agree not to post any personal medical data or information related to the study on any website or social media site until the entire trial has completed

Exclusion Criteria

  • Known hypersensitivity to lasmiditan, or to any excipient of lasmiditan oral tablets - History or evidence of hemorrhagic stroke, epilepsy, or any other condition placing the participant at increased risk of seizures - History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo, Meniere's disease, vestibular migraine, and other vestibular disorders - History of diabetes mellitus with complications (diabetic retinopathy, nephropathy, or neuropathy) - History of orthostatic hypotension with syncope - Significant renal or hepatic impairment in the opinion of the investigator or if they meet hepatic monitoring criteria - Participants who, in the investigator's judgment, are actively suicidal and therefore deemed to be at significant risk for suicide - History, within past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (eg, hemicranias continua, medication overuse headache where headache frequency is ≥15 headache days per month) - Use of more than 3 doses per month of either opioids or barbiturates - Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes within 3 months prior to screening - Pregnant or breast-feeding women - History of drug or alcohol abuse/dependence within 1 year prior to screening - Any medical condition or clinical laboratory test which in the judgment of the investigator makes the participant unsuitable for the study - Currently enrolled in any other clinical study involving an investigational product - Relatives of, or staff directly reporting to, the Investigator - Participants who are employees of the sponsor

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
100 milligram (mg) Lasmiditan 		Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
  • Drug: Lasmiditan
    Administered orally.
    Other names:
    • LY573144
  • Drug: Placebo
    Administered orally.
Experimental
200 mg Lasmiditan 		Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
  • Drug: Lasmiditan
    Administered orally.
    Other names:
    • LY573144
  • Drug: Placebo
    Administered orally.
Placebo Comparator
Control 1 Sequence 		Control 1: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
  • Drug: Lasmiditan
    Administered orally.
    Other names:
    • LY573144
  • Drug: Placebo
    Administered orally.
Placebo Comparator
Control 2 Sequence 		Control 2: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
  • Drug: Lasmiditan
    Administered orally.
    Other names:
    • LY573144
  • Drug: Placebo
    Administered orally.
Experimental
100 mg Lasmiditan Maximum Extended Enrollment (MEE) 		Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
  • Drug: Lasmiditan
    Administered orally.
    Other names:
    • LY573144
  • Drug: Placebo
    Administered orally.
Experimental
200 mg Lasmiditan MEE 		Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
  • Drug: Lasmiditan
    Administered orally.
    Other names:
    • LY573144
  • Drug: Placebo
    Administered orally.
Placebo Comparator
Control 1 Sequence MEE 		Control 1: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
  • Drug: Lasmiditan
    Administered orally.
    Other names:
    • LY573144
  • Drug: Placebo
    Administered orally.
Placebo Comparator
Control 2 Sequence MEE 		Control 2: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
  • Drug: Lasmiditan
    Administered orally.
    Other names:
    • LY573144
  • Drug: Placebo
    Administered orally.
Experimental
Open Label Extension 		Participants initially received 100 mg Lasmiditan at the first OLE visit, with flexible dosing (50, 100, or 200 mg) thereafter to optimize efficacy and tolerability.
  • Drug: Lasmiditan
    Administered orally.
    Other names:
    • LY573144

More Details

Status
Completed
Sponsor
Eli Lilly and Company

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.